Achilles Therapeutics Plc ADR (ACHL) concluded trading on Thursady at a closing price of $1.36, with 5.6 million shares of worth about $7.61 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 49.45% during that period and on Thursady the price saw a gain of about 10.57%. Currently the company’s common shares owned by public are about 40.93M shares, out of which, 39.01M shares are available for trading.
However, the stock later moved at a day high price of 1.4300, or with a gain of 10.57%. Stock saw a price change of 39.50% in past 5 days and over the past one month there was a price change of 51.11%. Year-to-date (YTD), ACHL shares are showing a performance of 52.98% which increased to 20.35% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.74 but also hit the highest price of $1.25 during that period. The average intraday trading volume for Achilles Therapeutics Plc ADR shares is 497.60K. The stock is currently trading 39.55% above its 20-day simple moving average (SMA20), while that difference is up 48.97% for SMA50 and it goes to 46.98% higher than SMA200.
Achilles Therapeutics Plc ADR (NASDAQ: ACHL) currently have 40.93M outstanding shares and institutions hold larger chunk of about 45.60% of that.
The stock has a current market capitalization of $55.46M and its 3Y-monthly beta is at 0.97. It has posted earnings per share of -$1.90 in the same period. It has Quick Ratio of 8.55 while making debt-to-equity ratio of 0.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ACHL, volatility over the week remained 13.38% while standing at 9.72% over the month.
Analysts are in expectations that Achilles Therapeutics Plc ADR (ACHL) stock would likely to be making an EPS of -$0.14 in the current quarter, while forecast for next quarter EPS is -$0.56 and it is -$1.25 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.51 which is $0.22 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.61 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 24.45% while it is estimated to increase by 9.09% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on April 26, 2021 offering an Overweight rating for the stock and assigned a target price of $25 to it. Coverage by Oppenheimer stated Achilles Therapeutics Plc ADR (ACHL) stock as an Outperform in their note to investors on April 26, 2021, suggesting a price target of $23 for the stock. On April 26, 2021, JP Morgan Initiated their recommendations, while on April 26, 2021, Chardan Capital Markets Initiated their ratings for the stock with a price target of $27. Stock get a Buy rating from BofA Securities on April 26, 2021.
